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Abstract. Retinal edema should be defined as any increase of water of the retinal tissue
resulting in an increase in its volume. It may be of cytotoxic or vasogenic origin. Development
of vasogenic macular edema is dependent on a series of factors such as blood pressure, blood-
retinal barrier permeability, retinal cell damage, retinal tissue osmotic pressure and retinal
tissue compliance. Objective measurements of retinal thickness are now possible using the
Retinal Thickness Analyser. Localised measurements of blood-retinal barrier permeability
may also be obtained using the Retinal Leakage Analyser, a modified confocal scanning laser
fluorometer, while obtaining simultaneously angiographic images of the choroid and retina.
These new imaging techniques show that cytotoxic and vasogenic retinal edema may occur
independently in the early stages of diabetic retinopathy. These findings offer new perpectives
for designing novel therapeutic strategies.
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Introduction
Diabetes is the leading cause of new cases of legal blindness among working
age Americans. Insulin dependent diabetes mellitus (IDDM) or Type 1 carries
a higher risk of ocular complications, but because there are many more pa-
tients with non-insulin dependent diabetes mellitus (Type 2), the latter group
comprises a substantial proportion of patients with blinding sequelae. It has
been estimated in the United States that there are almost 75,000 new cases
of diabetic macular edema each year. These numbers are clearly on the rise,
and it is expected that by the year 2010, 10% of the American population will
suffer from diabetes, especially Type 2 [1].
Basic concepts of retinal edema
First, it is very important to define retinal edema. Retinal edema should clearly
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be defined as any increase of water of the retinal tissue resulting in an increase
in its volume, i.e., thickness.
This increase in water content of the retinal tissue may be initially intra-
cellular or extracellular. In the first case, also called cytotoxic edema, there is
an alteration of the cellular ionic exchanges with an excess of Na+ inside the
cell. In the second case, also called vasogenic edema, there is a predominantly
extracellular accumulation of fluid directly associated with an alteration of the
Blood-Retinal Barrier (BRB). In this latter situation Starling law applies and
any loss of equilibrium between hydrostatic, oncotic and osmotic pressure
gradients across the BRB contribute to further water movements and edema
formation.
In cytotoxic edema, there is initially not a true edema, only a redistribu-
tion of water from its normal extracellular location to the intracellular space,
causing cell damage, more edema and later release of vasoactive substances
which may induce vasogenic edema through alteration of the BRB.
The initial alteration in intracellular, or cytotoxic, edema may be a lack of
ATP+ with depolarization of the cell membranes, alteration of the cell ionic
pumps with an increase of extracellular K+ with glutamate release and an in-
crease of intracellular Ca+ [2]. It may also result from an excitatory release of
glutamate or lactic acidosis, activating Na+/ H+ transport and accumulation
of intracellular Na+.
Vasogenic edema results from a breakdown of the BRB with extracellular
deposition of macromolecules. The primary defect is in the BRB and the
accumulation of fluid is extracellular.
In this situation, the ‘force’ driving water across the capillary wall is the
result of a hydrostatic pressure difference 1P and an effective osmotic pres-
sure difference1piσ [3]. The equation regulating movements across the BRB
is, therefore:
(driving f orce) = Lp [(Pplasma − Ptissue)− σ (piplasma − pitissue)]
where Lp is the hydraulic conductivity or membrane permeability of the BRB
and σ , an osmotic reflection coefficient, Pplasma, the blood pressure, Ptissue, the
retinal tissue pressure, piplasma, blood osmotic pressure and pi tissue, the tissue
osmotic pressure.
The loss of equilibrium between these pressure gradients is of importance
only after alteration of the Blood-Retinal Barrier (BRB), contributing then to
water movements.
An increase in1P, contributing to retinal edema, may be due to an increase
in Pplasma or a decrease in Ptissue or both. An increase in Pplasma due to increased
systemic blood pressure does contribute to retinal edema formation only after
loss of autoregulation of retinal blood flow and alteration of the structural
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characteristics of the BRB. A decrease in Ptissue is an important component
that has not been given sufficient attention. Any loss in the cohesiveness of
the retinal tissue due to pathologies such as cyst formation, vitreous traction,
or pulling at the inner limiting membrane will lead to a decrease in Ptissue.
A decrease in Ptissue, or increased retinal tissue compliance may lead to fluid
accumulation, edema formation, and an increase in retinal thickness.
A decrease in 1pi , contributing to retinal edema, may occur due to in-
creased protein accumulation in the retina after breakdown of the BRB. Ex-
sudate formation and extravasation of proteins will draw more water into the
retina. This is the main factor provoking a decrease in 1pi , as a reduction
in plasma osmolarity high enough to contribute to edema formation is an
extremely rare event.
After a breakdown of the BRB the progression of retinal edema depends
directly on the 1P and 1pi gradients. In these situations, tissue compliance
becomes more important, influencing directly the rate of edema progression.
In summary: retinal edema may be, initially, exclusively intracellular or
extracellular. In the first case, it occurs without breakdown of the BRB. In the
second case, a breakdown of the BRB must be present.
Clinical evaluation of retinal edema
The clinical evaluation of macular edema has been characterized by its diffi-
culty. Direct and indirect ophthalmoscopy may show only an alteration of the
foveal reflexes. Stereoscopic fundus photography and slit-lamp microscopy
play an important role demonstrating changes in retinal volume in the macular
area but they are dependent on the observer experience and the results do not
offer a reproducible measurement of the volume change. The Early Treat-
ment Diabetic Retinopathy Study, defined that the following characteristics
indicate “clinically significant macular edema”:
(1) Thickening of the retina (as seen either by slit lamp biomicroscopy or
by stereo fundus photography) at or within 500 microns of the center of
the macula;
(2) Hard exsudates at or within 500 microns of the center of the macula,
associated with the thickening of the adjacent retina (but not residual
hard exsudates remaining after disappearance of retinal thickening); and
(3) A zone, or zones, of retinal thickening one disc area or larger size, any
part of which is within one disc diameter of the center of the macula.
This definition was proposed to take into special consideration the involve-
ment of the center of the macula and its relationship to visual loss.
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Imaging of macular edema
We have seen that in order to develop retinal edema an increase in retinal
volume must be present. This increase in volume is represented by an in-
crease in retinal thickness because of the anatomical architecture of the retina.
Recently, a new technique was become available that measures objectively
overall retinal thickness, the Retinal Thickness Analyser (RTA) [4].
We have defined retinal edema as any increase of water of the retinal tissue
resulting in an increase in its thickness. Any increase in retinal thickness is,
therefore, a direct measurement of retinal edema. It is of particular interest
that there are now two instruments capable of measuring non-invasively the
thickness of the retina, the Retinal Thickness Analyser and Optical Coher-
ence Tomography (OCT). Both methods depend on clear media but allow for
very precise measurement of minor changes in retinal thickness. The Retinal
Thickness Analyser measures a slit-lamp like image of the retina, using the
internal limiting membrane and the retinal pigment epithelium as references.
It is associated with reliable positioning in the retina and has very good re-
producibility. It is of particular value in situations of retinal edema, without
marked disorganization of the retina. Optical Coherence Tomography gives a
color-coded image of the optical density of the various cellular components
of the retina and is of special interest in the presence of advanced structural
changes in the retina like cyst formation, and to demonstrate vitreal traction
and surface abnormalitites of the retina.
BRB breakdown has been detected by fluorescein angiography and meas-
ured by vitreous fluorometry. It is now possible, using the Retinal Leak-
age Analyser (RLA), a new instrument developed by our group, to perform
localised measurements of the permeability of the BRB with simultaneous
imaging of the retina [5]. Thus, quantitative maps of retinal thickness and
quantitative maps of retinal fluorescein leakage, indicative of BRB permeab-
ility can be obtained simultaneously, making sure that they are from the
same location in the retina. All these examinations and measurements are
performed in a clinical environment.
We have now, therefore, the means to acquire more data on retinal edema.
By measuring retinal thickness we characterize the location of the edema
and are capable of following its evolution. Next, it is important to determine
whether it is associated with breakdown of the BRB, i.e., whether it is vaso-
genic. The absence of a breakdown of the BRB would indicate a situation of
increased thickness due to intracellular or cytotoxic edema.
Furthermore, in a situation of vasogenic edema, information about1P and
1pi may be obtained using the OCT [6]. The presence of cysts and vitreal
traction can be demonstrated very easily by this instrument, indicating loss
of cohesiveness of the retinal tissue and demonstrating situations facilitating
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Figure 1. (a) Diabetic eye showing no visible signs of retinopathy on funduscopy. Left –
RTA – map of retinal thickness (µm). Right – RLA – map of fluorescein leakage (10−7cm/s)
(normal values are in the range of blues and dark green; the white cross shows the center of
the fovea). Note the presence of areas of thickening appearing independently from the leakage
sites (arrows). (b). Diabetic eye with minimal retinopathy changes. Left – RTA – map of retinal
thickness (µm). Right – RLA – map of fluorescein leakage (10−7cm/s) (normal values are in
the range of blues and dark green; the white cross shows the center of the fovea). Note the
zones of increased thickness correlated to sites of increased fluorescein leakage (arrows).
Figure 2. Image of Optical Coherence Tomography showing cyst formation in a situation of
advanced diabetic macular edema.
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fluid accumulation in the retina. Accumulation of proteins and exsudates in
the retina may also become apparent as a localised increase of optical density
of the retinal structures.
With these new imaging methods it is now possible to clinically follow ret-
inal edema and to obtain information about its type (cytotoxic or vasogenic),
as well as about other important factors involved in its progression.
Imaging of retinal edema in diabetes
The application of these new methods to the evaluation of diabetic macular
edema has shown that both types of retinal edema, cytotoxic and vasogenic,
occur in the diabetic retina before the development of clinical significant
macular edema.
Preliminary results have shown that in diabetic eyes without vascular patho-
logy visible on ophthalmoscopic examination it is possible to find localized
areas of increased retinal thickness without associated breakdown of the BRB
in the posterior pole (Figure 1a). However, in other locations it is possible to
find a clear association between zones of increased thickness and sites of
increased fluorescein leakage and breakdown of the BRB (Figure 1b).
We think that in the diabetic retina the two types of retinal edema occur
together from the initial steps of the disease. Cytotoxic edema may well be
the first. Recent results from our laboratory indicate that the retinal vessels
increase glucose transport into the retina in the presence of hyperglycemia,
thus creating an excessive accumulation of glucose in the inner retina [7]. Ab-
normally elevated glucose levels in the retina in diabetes lead to an increase
in lactate and frutose production. The increase in the ratio lactate-pyruvate
is similar to that induced by hypoxia. Williamson and co-workers [8] have
called this a situation ‘pseudo hypoxia’ induced by the hyperglycemia. A nat-
ural outcome is the development of intracellular ionic changes and excessive
glutamate release causing intracellular edema. Later on, progressive retinal
cellular damage would result in the release of vasoactive substances such as
nitric oxide and free radicals, inducing vascular damage and breakdown of
the BRB with protein leakage and extracellular edema (vasogenic).
Studies directed to the earliest stages of retinal involvement of diabetes
using simultaneously the RTA and the RLA are already offering new insights
into our understanding of diabetic retinal disease and diabetic retinal edema.
In more advanced situations of retinal pathology associated with marked ret-
inal edema, OCT examination may show alterations in retinal structure and
cyst formation (Figure 2).
A better targeted therapy of diabetic retinal edema will be derived from
the application of these new methods of retinal imaging.
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In diabetic macular edema, determining which type of retinal edema pre-
dominates (cytotoxic or vasogenic) may, in the future, influence the choice
of neuroprotective or vasoprotective agents. Neuroprotective agents that are
likely candidates include calcium-channel blockers, glutamate-receptor ant-
agonists and antioxidants. Some of the vasoprotective agents that offer prom-
ising perspectives are nitric oxide synthethase inhibitors, Advanced Glycation
Endproduct (AGE) formation inhibitors and Angiotensin Conversion Enzyme
(ACE) inhibitors [9–11].
These drugs may be used in the near future to protect the retinal cells and
the BRB from the damage caused by the increased and abnormal glucose
metabolism occurring in the diabetic retina and thus delay the development
of the retinopathy.
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